EDGEWISE THERAPEUTICS INC (EWTX)
US28036F1057 - Common Stock
EWTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. EWTX has a great financial health rating, but its profitability evaluates not so good. EWTX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year EWTX has reported negative net income.
In the past year EWTX has reported a negative cash flow from operations.
In the past 5 years EWTX always reported negative net income.
In the past 5 years EWTX always reported negative operating cash flow.
1.2 Ratios
EWTX has a Return On Assets of -24.31%. This is comparable to the rest of the industry: EWTX outperforms 60.00% of its industry peers.
EWTX has a better Return On Equity (-25.42%) than 68.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.31% | ||
| ROE | -25.42% | ||
| ROIC | N/A |
ROA(3y)-20.96%
ROA(5y)-23.12%
ROE(3y)-22.18%
ROE(5y)-24.3%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EWTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for EWTX has been increased compared to 1 year ago.
There is no outstanding debt for EWTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
EWTX has an Altman-Z score of 77.30. This indicates that EWTX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 77.30, EWTX belongs to the top of the industry, outperforming 98.95% of the companies in the same industry.
EWTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 77.3 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
EWTX has a Current Ratio of 26.35. This indicates that EWTX is financially healthy and has no problem in meeting its short term obligations.
EWTX has a Current ratio of 26.35. This is amongst the best in the industry. EWTX outperforms 96.32% of its industry peers.
EWTX has a Quick Ratio of 26.35. This indicates that EWTX is financially healthy and has no problem in meeting its short term obligations.
EWTX has a Quick ratio of 26.35. This is amongst the best in the industry. EWTX outperforms 96.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 26.35 | ||
| Quick Ratio | 26.35 |
3. Growth
3.1 Past
EWTX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.63%.
EPS 1Y (TTM)-5.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 2.39% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y3.49%
EPS Next 2Y-8.65%
EPS Next 3Y-10.58%
EPS Next 5Y2.39%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
EWTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EWTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
EWTX's earnings are expected to decrease with -10.58% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.65%
EPS Next 3Y-10.58%
5. Dividend
5.1 Amount
EWTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EDGEWISE THERAPEUTICS INC
NASDAQ:EWTX (12/20/2024, 8:07:55 PM)
After market: 30.78 0 (0%)30.78
-0.02 (-0.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners87.03%
Inst Owner Change-0.46%
Ins Owners0.49%
Ins Owner Change0.49%
Market Cap2.91B
Analysts85
Price Target46.92 (52.44%)
Short Float %7.76%
Short Ratio6.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.08%
Min EPS beat(2)3.18%
Max EPS beat(2)4.98%
EPS beat(4)3
Avg EPS beat(4)4.86%
Min EPS beat(4)-6.17%
Max EPS beat(4)17.47%
EPS beat(8)6
Avg EPS beat(8)5.71%
EPS beat(12)8
Avg EPS beat(12)3.87%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.49%
PT rev (3m)36.9%
EPS NQ rev (1m)0.96%
EPS NQ rev (3m)0.36%
EPS NY rev (1m)-0.53%
EPS NY rev (3m)-0.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.96 | ||
| P/tB | 5.96 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.5
EYN/A
EPS(NY)-1.87
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.15
OCFYN/A
SpS0
BVpS5.16
TBVpS5.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.31% | ||
| ROE | -25.42% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-20.96%
ROA(5y)-23.12%
ROE(3y)-22.18%
ROE(5y)-24.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 60.97% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 26.35 | ||
| Quick Ratio | 26.35 | ||
| Altman-Z | 77.3 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)706.19%
Cap/Depr(5y)474.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.2%
EPS Next Y3.49%
EPS Next 2Y-8.65%
EPS Next 3Y-10.58%
EPS Next 5Y2.39%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-43.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-37.09%
EBIT Next 3Y-24.35%
EBIT Next 5Y14.96%
FCF growth 1Y-109.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-116.76%
OCF growth 3YN/A
OCF growth 5YN/A